TY - JOUR
T1 - Spontaneous regression of transverse colon cancer with high-frequency microsatellite instability
T2 - A case report and literature review
AU - Karakuchi, Nozomi
AU - Shimomura, Manabu
AU - Toyota, Kazuhiro
AU - Hinoi, Takao
AU - Yamamoto, Hideki
AU - Sadamoto, Seiji
AU - Mandai, Koichi
AU - Egi, Hiroyuki
AU - Ohdan, Hideki
AU - Takahashi, Tadateru
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/1/15
Y1 - 2019/1/15
N2 - Background: Spontaneous regression (SR) of colorectal cancer (CRC) is extremely rare, and only few cases have been reported. Although it is not yet clarified, a plausible mechanism for SR of CRC is an immunological event. Case presentation: In this report, we present the case of SR of primary CRC in a 78-year-old man. Preoperative colonoscopy was performed, and a type 2 tumor measuring 30 mm in diameter in the transverse colon was detected. The biopsy revealed a poorly differentiated adenocarcinoma. Colectomy was performed 2 months after initial colonoscopy. During the surgery, only a 10-mm ulcer harboring a polypoid lesion measuring 8.5 mm was detected in the resected tissue; no other masses or carcinoma cells were seen on histological examination. Afterwards, the biopsy specimens were reanalyzed, and immunohistological analysis verified this as adenocarcinoma with stroma-infiltrating lymphocytes. Further analysis revealed a loss of two mismatch repair proteins, suggesting sporadic high-frequency microsatellite instability (MSI-H). Conclusion: According to previous literature, a common site of SR in CRC is the proximal colon, which is a feature of MSI-H CRC. However, our report showed a rare case of SR of CRC, which was in the transverse colon, with MSI-H present. This report indicates a relationship between immunological features of MSI-H and the occurrence of SR of CRC. A better understanding of this phenomenon and the mechanisms involved will have significant preventive and therapeutic implications for CRC, including anti-PD-1 immune checkpoint inhibitor therapy.
AB - Background: Spontaneous regression (SR) of colorectal cancer (CRC) is extremely rare, and only few cases have been reported. Although it is not yet clarified, a plausible mechanism for SR of CRC is an immunological event. Case presentation: In this report, we present the case of SR of primary CRC in a 78-year-old man. Preoperative colonoscopy was performed, and a type 2 tumor measuring 30 mm in diameter in the transverse colon was detected. The biopsy revealed a poorly differentiated adenocarcinoma. Colectomy was performed 2 months after initial colonoscopy. During the surgery, only a 10-mm ulcer harboring a polypoid lesion measuring 8.5 mm was detected in the resected tissue; no other masses or carcinoma cells were seen on histological examination. Afterwards, the biopsy specimens were reanalyzed, and immunohistological analysis verified this as adenocarcinoma with stroma-infiltrating lymphocytes. Further analysis revealed a loss of two mismatch repair proteins, suggesting sporadic high-frequency microsatellite instability (MSI-H). Conclusion: According to previous literature, a common site of SR in CRC is the proximal colon, which is a feature of MSI-H CRC. However, our report showed a rare case of SR of CRC, which was in the transverse colon, with MSI-H present. This report indicates a relationship between immunological features of MSI-H and the occurrence of SR of CRC. A better understanding of this phenomenon and the mechanisms involved will have significant preventive and therapeutic implications for CRC, including anti-PD-1 immune checkpoint inhibitor therapy.
KW - Colorectal cancer
KW - Microsatellite instability
KW - Spontaneous regression
UR - http://www.scopus.com/inward/record.url?scp=85059987984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059987984&partnerID=8YFLogxK
U2 - 10.1186/s12957-018-1552-x
DO - 10.1186/s12957-018-1552-x
M3 - Review article
C2 - 30646898
AN - SCOPUS:85059987984
SN - 1477-7819
VL - 17
JO - World Journal of Surgical Oncology
JF - World Journal of Surgical Oncology
IS - 1
M1 - 19
ER -